Does UPADACITINIB Cause Therapeutic product effect delayed? 55 Reports in FDA Database
Grow Your Own Natural Pharmacy at Home
Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.
According to the FDA Adverse Event Reporting System (FAERS), 55 reports of Therapeutic product effect delayed have been filed in association with UPADACITINIB (Rinvoq). This represents 0.1% of all adverse event reports for UPADACITINIB.
55
Reports of Therapeutic product effect delayed with UPADACITINIB
0.1%
of all UPADACITINIB reports
0
Deaths
2
Hospitalizations
How Dangerous Is Therapeutic product effect delayed From UPADACITINIB?
Of the 55 reports, 2 (3.6%) required hospitalization.
Is Therapeutic product effect delayed Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for UPADACITINIB. However, 55 reports have been filed with the FAERS database.
What Other Side Effects Does UPADACITINIB Cause?
Pain (4,444)
Arthralgia (3,815)
Drug ineffective (3,384)
Covid-19 (2,978)
Rheumatoid arthritis (2,730)
Pain in extremity (2,353)
Fatigue (2,153)
Fall (2,081)
Surgery (2,037)
Therapy interrupted (1,741)
What Other Drugs Cause Therapeutic product effect delayed?
ADALIMUMAB (244)
TOFACITINIB (178)
CARBIDOPA\LEVODOPA (168)
SECUKINUMAB (162)
POLYETHYLENE GLYCOL 3350 (125)
RIMEGEPANT (120)
TASIMELTEON (93)
DUPILUMAB (90)
IBUPROFEN (88)
DICLOFENAC (85)
Which UPADACITINIB Alternatives Have Lower Therapeutic product effect delayed Risk?
UPADACITINIB vs URAPIDIL
UPADACITINIB vs UREA
UPADACITINIB vs URIDINE TRIACETATE
UPADACITINIB vs UROFOLLITROPIN
UPADACITINIB vs URSODIOL